Completed PHASE1 INTERVENTIONAL 2-arm NCT02070237

Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis

Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily

Sponsor: MemorialCare Health System

Conditions Complications; Cesarean Section Obesity Obesity, Morbid Postpartum Deep Phlebothrombosis Pregnancy Pulmonary Embolism Venous Thromboembolism

Interventions Enoxaparin

Updated 7 times since 2017 Last updated: Oct 22, 2015 Started: Aug 31, 2013 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Complications; Cesarean Section and Obesity and is currently completed. MemorialCare Health System leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MemorialCare Health System

Data source: MemorialCare Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Long Beach, United States